Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth.

What Was Tested

Researchers studied Magnesium Sulfate in this randomized controlled trial publication.

To assess the neuroprotective effect of magnesium sulfate (MgSO4 ) in preterm children exposed to chorioamnionitis.

Why It Was Studied

Singleton, non-anomalous pregnancies with clinical chorioamnionitis, delivering at ≥24 weeks of gestation.

Who Took Part

PubMed indexes the participants as infants and adults, both men and women.

How the Study Was Run

The design is described as randomized, placebo-controlled and multicenter.

Random assignment meant chance, not the researchers, decided who got Magnesium Sulfate and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Magnesium Sulfate could be set against what happens without it.

Running at several centres spread the Magnesium Sulfate study over different clinics and patient groups.

Singleton, non-anomalous pregnancies with clinical chorioamnionitis, delivering at ≥24 weeks of gestation, were selected.

Cases were exposed to antepartum MgSO4; controls received placebo.

All data were analysed by intention to treat.

Univariate and multivariate analyses were performed.

What Was Measured

PubMed files the paper under topics including Cerebral Palsy, Chorioamnionitis, Infant Mortality, Infant, Premature, Diseases, Magnesium Sulfate, Neurodevelopmental Disorders and Neuroprotective Agents.

The authors tagged it with the keywords preterm.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and multicenter study of Magnesium Sulfate.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (BJOG : an international journal of obstetrics and gynaecology), a journal based in England.

More context: all human trials.